ArticlePloS one2026
Revisiting differential expression analysis: An updated six-dimensional comparative study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differential expression (DE) analysis is probably the most prevalent task for transcriptomic studies. However, recent technological advances have seen a revival of methodological interest in DE algorithms. In this study, we performed a comprehensive updated comparative study of 12 representative DE methods using 80 simulated and real datasets. We assessed the adaptability of these methods across varying sample sizes and diverse data scenarios. This evaluation compiled a six-dimensional overview of key properties: detection accuracy, sensitivity at a low false discovery rate, false positives, stability, robustness to outliers, and robustness under noisy conditions. Strikingly, no single methods outperformed others across all evaluation criteria and sample sizes, emphasizing data-specific and scenario-specific method choice. At the widely adopted small-sample size of n = 3, ABSSeq generally outperformed other methods. As sample size increased to n = 5, the sensitivity of DESeq2 and two edgeR v4 algorithms (QLF slightly better than LRT) also raise up under a stringent false-positive control. DESeq had even fewer false positives than DESeq2, at the price of reduced sensitivity. In terms of robustness, Wilcoxon and ROTS are robust to noises for small sample sizes. Moreover, Wilcoxon is also robust to outliers, together with several other methods (ABSSeq, voom, and T.test). NBPSeq and most methods had a good stability even at small sample sizes, except three methods (ROTS, DSS, and T.test). For larger sample sizes (n > 30), all methods performed much better. Finally, we provided a "BaGua (eight trigrams)" map summarizing the multi-dimensional performances of methods, as well as a tree diagram guiding practical method selection. Together, this study outlines a systematic and updated benchmarking framework for DE analysis, emphasizing a balance between accuracy and consistency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.